Who
Richard Dana Ono
Director
Company insider
Files Form 4 as: Director, Lipocine; Director, Inhibitor Therapeutics.
In numbers
- Trades disclosed
- 39
- Buys
- 2
- Sells
- 1
- Bought
- $22K
- Sold
- $3,036
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 6 Jan 2014
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $3,8631,764 at $2.19 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $3,8631,764 at $2.19 | filing |
| 4 Jun 2025filed 5 Jun 2025 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $5,6451,764 at $3.20 | filing |
| 5 Jun 2024filed 7 Jun 2024 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $12K1,764 at $7.05 | filing |
| 10 May 2023filed 12 May 2023 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $8,10030,000 at $0.27 | filing |
| 20 Mar 2023filed 20 Mar 2023 | LPCN LipocineBiotechnology | SEC FORM 4 Bought | $1,3604,000 at $0.34 | filing |
| 8 Jun 2022filed 10 Jun 2022 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $20K22,000 at $0.92 | filing |
| 9 Jun 2021filed 10 Jun 2021 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $28K22,000 at $1.26 | filing |
| 22 Dec 2020filed 28 Dec 2020 | Inhibitor Therapeuticsoption or derivative | SEC FORM 4 Code A | —754,839 at $0.00 | filing |
| 16 Dec 2020filed 17 Dec 2020 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,250 at $0.00 | filing |
| 16 Dec 2020filed 17 Dec 2020 | LPCN LipocineBiotechnology | SEC FORM 4 Code M | —5,250 at $0.00 | filing |
| 10 Jun 2020filed 10 Jun 2020 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $21K22,000 at $0.96 | filing |
| 20 Mar 2020filed 24 Mar 2020 | Inhibitor Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 12 Jun 2019filed 14 Jun 2019 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $17K10,000 at $1.68 | filing |
| 3 Feb 2019filed 5 Feb 2019 | HedgePath Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —657,895 at $0.00 | filing |
| 27 Jun 2018filed 28 Jun 2018 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $27K20,000 at $1.33 | filing |
| 13 Mar 2018filed 15 Mar 2018 | HedgePath Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —253,000 at $0.00 | filing |
| 13 Mar 2018filed 15 Mar 2018 | HedgePath Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 29 Dec 2017filed 2 Jan 2018 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
| 29 Dec 2017filed 2 Jan 2018 | LPCN LipocineBiotechnology | SEC FORM 4 Code M | —1,750 at $0.00 | filing |
News
Lipocine (NASDAQ:LPCN) & Harmony Biosciences (NASDAQ:HRMY) Head-To-Head AnalysisLPCN · dailypolitical.com · 14 Oct 2026Lipocine (NASDAQ: LPCN) wins Health Canada approval for TLANDO in CanadaLPCN · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Richard Dana Ono; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.